Reply to the letter to the editor 'Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer' Tannock and Pond

Affiliations

¹ University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, USA. Electronic address: hrugo@medicine.ucsf.edu.
² Institut Multidisciplinaire D'Oncologie, Genolier, Switzerland.

Free article

Comment

H S Rugo et al. Ann Oncol. 2014 Oct.

Free article

. 2014 Oct;25(10):2096-2098.

doi: 10.1093/annonc/mdu373. Epub 2014 Aug 1.

¹ University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, USA. Electronic address: hrugo@medicine.ucsf.edu.
² Institut Multidisciplinaire D'Oncologie, Genolier, Switzerland.

No abstract available

Comment on

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.
Rugo HS, Pritchard KI, Gnant M, Noguchi S, Piccart M, Hortobagyi G, Baselga J, Perez A, Geberth M, Csoszi T, Chouinard E, Srimuninnimit V, Puttawibul P, Eakle J, Feng W, Bauly H, El-Hashimy M, Taran T, Burris HA 3rd. Rugo HS, et al. Ann Oncol. 2014 Apr;25(4):808-815. doi: 10.1093/annonc/mdu009. Epub 2014 Mar 10. Ann Oncol. 2014. PMID: 24615500 Free PMC article. Clinical Trial.
Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer.
Aapro M, Andre F, Blackwell K, Calvo E, Jahanzeb M, Papazisis K, Porta C, Pritchard K, Ravaud A. Aapro M, et al. Ann Oncol. 2014 Apr;25(4):763-773. doi: 10.1093/annonc/mdu021. Ann Oncol. 2014. PMID: 24667713 Review.
Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer.
Tannock IF, Pond GR. Tannock IF, et al. Ann Oncol. 2014 Oct;25(10):2096. doi: 10.1093/annonc/mdu371. Epub 2014 Aug 1. Ann Oncol. 2014. PMID: 25085505 No abstract available.